These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11698713)

  • 41. Trial in youngest group points to HIV treatment overhaul.
    Dolgin E
    Nat Med; 2011 Apr; 17(4):393. PubMed ID: 21475208
    [No Abstract]   [Full Text] [Related]  

  • 42. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
    Taburet AM; Raguin G; Le Tiec C; Droz C; Barrail A; Vincent I; Morand-Joubert L; Chêne G; Clavel F; Girard PM
    Clin Pharmacol Ther; 2004 Apr; 75(4):310-23. PubMed ID: 15060509
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [HIV therapy in childhood. Also once daily lopinavir/r is effective].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():55. PubMed ID: 16385877
    [No Abstract]   [Full Text] [Related]  

  • 45. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
    Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
    AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
    Delaugerre C; Mathez D; Peytavin G; Berthé H; Long K; Galperine T; de Truchis P
    AIDS; 2007 May; 21(9):1210-3. PubMed ID: 17502734
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treating advanced HIV infection.
    Boffito M; Bonora S; Sinicco A; Raiteri R; Milia MG; Khoo SH; Hoggard PG; Back DJ; Di Perri G
    J Acquir Immune Defic Syndr; 2003 Nov; 34(3):344-5. PubMed ID: 14600582
    [No Abstract]   [Full Text] [Related]  

  • 48. ICAAC eyes PIs, NNRTIs, and STIs.
    Mascolini M
    IAPAC Mon; 2000 Dec; 6(12):362-75. PubMed ID: 11299547
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.
    Else LJ; Taylor S; Back DJ; Khoo SH
    Antivir Ther; 2011; 16(8):1149-67. PubMed ID: 22155899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Newest protease inhibitor Kaletra has a unique profile.
    Murphy MJ
    HIV Clin; 2001; 13(1):6-7. PubMed ID: 11810817
    [No Abstract]   [Full Text] [Related]  

  • 51. [From research to clinical practice: use of lopinavir/ritonavir in monotherapy].
    Valencia-Ortega ME; Moreno-Celda V
    Enferm Infecc Microbiol Clin; 2008 Dec; 26(10):671-2. PubMed ID: 19100200
    [No Abstract]   [Full Text] [Related]  

  • 52. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
    Barreiro P; Soriano V; Blanco F; Casimiro C; de la Cruz JJ; González-Lahoz J
    AIDS; 2000 May; 14(7):807-12. PubMed ID: 10839588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.
    Martínez E; Gatell JM
    AIDS; 2007 Aug; 21(13):1829-30. PubMed ID: 17690588
    [No Abstract]   [Full Text] [Related]  

  • 55. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.
    Khanlou H; Graham E; Brill M; Farthing C
    AIDS; 2002 Mar; 16(5):797-8. PubMed ID: 11964539
    [No Abstract]   [Full Text] [Related]  

  • 56. Underpowered clinical trials of antiretroviral treatment.
    Arribas JR; Pulido F
    JAMA; 2002 Nov; 288(17):2120; author reply 2120-1. PubMed ID: 12413367
    [No Abstract]   [Full Text] [Related]  

  • 57. CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study.
    Wood E; Hogg RS; Yip B; O'Shaughnessy MV; Montaner JS
    J Acquir Immune Defic Syndr; 2003 Nov; 34(3):347-8. PubMed ID: 14600584
    [No Abstract]   [Full Text] [Related]  

  • 58. Antivirals update.
    Proj Inf Perspect; 1998 Dec; (26):8-10. PubMed ID: 11366501
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Antiretroviral therapy in patients infected with HIV-1].
    Corti ME
    Medicina (B Aires); 1998; 58 Suppl 1():49-56. PubMed ID: 9674248
    [No Abstract]   [Full Text] [Related]  

  • 60. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
    Tilling R; Kinloch S; Goh LE; Cooper D; Perrin L; Lampe F; Zaunders J; Hoen B; Tsoukas C; Andersson J; Janossy G;
    AIDS; 2002 Mar; 16(4):589-96. PubMed ID: 11873002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.